Tanvex BioPharma, Inc. (TPE:6541)

Taiwan · Delayed Price · Currency is TWD

39.00

+1.60 (4.28%)

May 29, 2026, 1:30 PM CST

Revenue by Segment

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016
Biotechnology (Startups)	400.97M	34.68M	61.41M	22.40M	5.41M
Biotechnology (Startups) Growth	1056.27%	-43.53%	174.11%	314.43%	1702.00%
Total	400.97M	34.68M	61.41M	22.40M	5.41M
Total Growth	1056.27%	-43.53%	174.11%	314.43%	1702.00%

Revenue by Geography

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016
Taiwan	170.03M	-	53.70M	22.40M	5.41M
Taiwan Growth	-	-	139.70%	314.43%	1702.00%
United States	230.94M	34.68M	7.71M	-	-
United States Growth	565.95%	349.84%	-	-	-
Total	400.97M	34.68M	61.41M	22.40M	5.41M
Total Growth	1056.27%	-43.53%	174.11%	314.43%	1702.00%

Source: S&P Global Market Intelligence.